AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

By admin
An expert panel at ELCC 2025 reviews the MARIPOSA trial’s implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.